Journal of Diabetes Research / 2020 / Article / Tab 3 / Review Article
The Role of Recombinant Proteins and Growth Factors in the Management of Diabetic Foot Ulcers: A Systematic Review of Randomized Controlled Trials Table 3 Characteristics of RCTs that evaluated EGF safety and effectiveness.
Ref Study Intervention Type of control Size and the oldness of the wound No. of patients Antibiotic application during the treatment period (if needed) Baseline HbA1C (%) Types of wound and grade of wound Dressing type Offloading Treatment duration Follow-up period posttherapy [16 ] RCT Thrice-per-week intralesional application of 75 μ g rhEGF Placebo >2 cm2 31 Y NM Any grade Antimicrobial dressing with ionic silver Y 8 weeks NM [17 ] RCT EGF (75 or 25 μ g) three times per week and standard good wound care Placebo > 1 cm2 149 Y Y Wagner’s grade III or IV Saline-moistened gauze Y 8 weeks 12 months [18 ] RCT Topical application of beta urogastrone (rhEGF) gel. It was applied as a thick layer Betadine dressing 2-50 cm2 in the area 50 NM NM Wagner grades I and II Dry sterilized gauze NM 8 weeks NM [19 ] RCT Group 1 (control) was treated with Actovegin 5% cream (Actovegin), group 2 with Actovegin plus 0.02% (wt/wt) hEGF, and group 3 with Actovegin plus 0.04% (wt/wt) hEGF Placebo NM 61 NM <12% Wagner grades I and II Saline dressing NM 12 weeks 24 weeks [20 ] RCT phase III rhEGF 150 μ g/g gel Placebo 2-50 cm2 60 NM NM Wagner grades I and II NM NM 15 weeks NM
EGF: Epidermal growth factor, Y: yes, N: no, NM: not mentioned.
